Literature DB >> 17409342

Thiazolidinediones: new evidence of bone loss.

Ann V Schwartz, Deborah E Sellmeyer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17409342     DOI： 10.1210/jc.2007-0328

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  6 in total

Review 1.  Minireview: nuclear receptor regulation of osteoclast and bone remodeling.

Authors:  Zixue Jin; Xiaoxiao Li; Yihong Wan
Journal:  Mol Endocrinol       Date:  2014-12-30

2.  Thiazolidinediones and bone.

Authors:  Alberto Falchetti; Laura Masi; Maria Luisa Brandia
Journal:  Clin Cases Miner Bone Metab       Date:  2007-05

3.  Pioglitazone attenuates valvular calcification induced by hypercholesterolemia.

Authors:  Yi Chu; Donald D Lund; Robert M Weiss; Robert M Brooks; Hardik Doshi; Georges P Hajj; Curt D Sigmund; Donald D Heistad
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-01-03       Impact factor: 8.311

Review 4.  Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment.

Authors:  Tim C M A Schreuder; Bart J Verwer; Carin M J van Nieuwkerk; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

5.  Dextromethorphan inhibits osteoclast differentiation by suppressing RANKL-induced nuclear factor-κB activation.

Authors:  Karl Wu; Tzu-Hung Lin; Houng-Chi Liou; Dai-Hua Lu; Yi-Ru Chen; Wen-Mei Fu; Rong-Sen Yang
Journal:  Osteoporos Int       Date:  2013-02-12       Impact factor: 4.507

6.  PPARdelta Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities.

Authors:  Mylène Perreault; David V Erbe; James F Tobin
Journal:  PPAR Res       Date:  2008-10-29       Impact factor: 4.964
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.